Clinical trials: Breast Cancer, suspended
Breast Cancer
Postoperative Identification of Tumor Cells At the Lumpectomy Site of Patients with Early Breast Cancer
For early breast cancer, local surgery followed by breast radiation is a standard local treatment. It has been found that the original primary tumor site, the lumpectomy site, is the commonest location of local relapse.
- Trial name
- NCT04339517
- Testing
- Aspiration of seroma fluid
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Ductal Carcinoma in Situ
Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
The standard surgical approach for all patients undergoing mastectomy for the treatment of non-invasive, ductal carcinoma in situ (DCIS) is to perform axillary lymph node staging through use of a traditional sentinel lymph node…
- Trial name
- NCT06868238
- Testing
- Magtrace
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Breast Cancer
Diffusion-Weighted MRI for Breast Cancer Screening in Women With a Personal History of Breast Cancer
Women with personal history of breast cancer (PHBC) are at risk of developing second breast cancers in the conserved and contralateral breast.
- Trial name
- NCT04619186
- Where
- South Korea
- Volunteers
- 1,694 people
- Sponsor
- Seoul National University Hospital
Adult Solid Tumor
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug…
- Trial name
- ANCERS-2 (NCT03253575)
- Testing
- CANscript
- Where
- 30 sites in United States
- Volunteers
- 800 people
- Sponsor
- Mitra RxDx, Inc.
Breast Cancer
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
Early identification of patients at risk for cardiotoxicity represent a primary goal for cardiologist and oncologist From all adjuvant trials echocardiography is ideal for evaluating Left Ventricular function though its operator…
- Trial name
- NCT02062983
- Testing
- Herceptin
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- National Guard Health Affairs
Female Breast Cancer
Breast Cancer in Young Women: Is it Different?
Breast cancer is the leading cancer among women in Saudi Arabia representing almost the third of cancer diagnosed in Saudi women. Breast cancer in Saudi women is more frequently observed at young age.
- Trial name
- YoungWomen (NCT01320488)
- Where
- Saudi Arabia
- Volunteers
- 600 people
- Sponsor
- National Guard Health Affairs
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of ASTX727 when given in combination with a usual approach of treatment with paclitaxel and pembrolizumab in patients with triple-negative breast cancer that has…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Trial name
- NCT05673200
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Polymorphism, CYP19
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor.
- Conditions
- Polymorphism, CYP19, Aromatase Inhibitor
- Trial name
- CYP19 (NCT01137136)
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Gastrointestinal Cancer, Head and Neck Cancer
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects.
- Conditions
- Gastrointestinal Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation
- Trial name
- NCT04541381
- Testing
- Availability of clinical decision support based on pharmacogenomic results.
- Where
- United States
- Volunteers
- 860 people
- Sponsor
- University of Chicago
Liver Metastases, Liver Metastasis Colon Cancer
DNX-2440 for Resectable Colorectal Liver Metastasis
The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery.
- Conditions
- Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer
- Trial name
- NCT04714983
- Testing
- DNX-2440
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- DNAtrix, Inc.
Vaginal Atrophy, Genitourinary System; Disorder, Female
A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes
The focus of this study is to assess breast cancer survivors perspectives of Viveve® Treatment using patient reported outcome tools with a focus on symptoms associated with vulvovaginal atrophy/genitourinary syndrome of menopause…
- Conditions
- Vaginal Atrophy, Genitourinary System; Disorder, Female, Vaginal Abnormality, Sexual Dysfunction
- Trial name
- BRAVO (NCT03547089)
- Testing
- Viveve®
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- W. Grant Stevens, MD
Breast Cancer Related Lymphedema
Physiotherapy Program Impact on Breast Cancer-Related Lymphedema
Breast Cancer Related Lymphedema (BCRL) is a sequela resulting from the application of certain treatments, such as axillary lymph node dissection and regional lymph node radiation.
- Trial name
- NCT06491654
- Testing
- 12-week supervised exercise
- Where
- Spain
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- European University Miguel de Cervantes
Breast Cancer, Triple-negative Breast Cancer
Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment
This study is looking at how an imaging test could help doctors understand if a patient with early breast cancer will respond to drugs that use the patient's immune system to fight cancer.
- Trial name
- NCT04803084
- Testing
- Tempus assay, Advanced pathology 1, Advanced pathology 2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Laura Kennedy
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory)…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Refractory Breast Carcinoma
- Trial name
- NCT04120246
- Testing
- Alpha-tocopheryloxyacetic Acid, Trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veana Therapeutics
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of…
- Trial name
- NCT05656131
- Testing
- Fluzoparib, Fluzoparib+Camrelizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- wang shusen
Breast Cancer
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)
This intraoperative study is a prospective study analyzing specimens from fifty subjects. Patients scheduled to undergo breast-conserving surgery will be recruited in accordance with the inclusion and exclusion criteria.
- Trial name
- NCT02313116
- Testing
- Interferometric Synthetic Aperture Microscopy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Diagnostic Photonics, Inc.
Breast Neoplasm Female, Cancer, Breast
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
This study is designed to evaluate the Sentinel BreastScan II as well as the analysis of data by Therma-Scan.
- Conditions
- Breast Neoplasm Female, Cancer, Breast, Thermography
- Trial name
- NCT03271853
- Testing
- Sentinel BreastScan II
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- First Sense Medical, LLC
Early-stage Breast Cancer, Breast Carcinoma
Pilot Trial of Preop Partial Radiation in Breast Cancer Patients
The purpose of our study is to assess the feasibility of preoperative partial breast (APBI) radiation in breast cancer patients. The primary outcome is the acute wound complication rate.
- Conditions
- Early-stage Breast Cancer, Breast Carcinoma, DCIS
- Trial name
- NCT07178665
- Testing
- Radiation: Accelerated Partial Breast Irradiation (APBI)
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Adenocarcinoma, HER2/Neu Negative
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back.
- Conditions
- Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7
- Trial name
- NCT02037529
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 39 sites in United States
- Volunteers
- 201 people
- Sponsor
- Academic and Community Cancer Research United